Relmada Therapeutics (RLMD) Depreciation and Depletion (2014 - 2021)
Relmada Therapeutics (RLMD) reported Depreciation and Depletion of $452.0 for Q2 2021, down 56.07% year-over-year from $1029.0 in Q2 2020, and down 43.92% on a QoQ basis from $806.0 in Q1 2021.
Relmada Therapeutics (RLMD) has 8 years of Depreciation and Depletion data on file, last reported at $452.0 in Q2 2021.
- Quarterly Depreciation and Depletion fell 56.07% year-over-year to $452.0 in Q2 2021, while the trailing twelve-month figure through Dec 2021 was $1258.0 (down 66.47% YoY) and the FY2021 annual result came in at $1258.0, down 66.47% from the prior year.
- Depreciation and Depletion slipped to $452.0 in Q2 2021 per RLMD's latest filing, from $806.0 in the prior quarter.
- Across five years, Depreciation and Depletion topped out at $23268.0 in Q1 2017 and bottomed at -$556.0 in Q4 2018.
- The 5-year median for Depreciation and Depletion is $1029.0 (2020), against an average of $3271.9.
- The widest annual swing landed in 2018, when Depreciation and Depletion plunged 195.53%; it then jumped 495.68% in 2019.
- Tracing RLMD's Depreciation and Depletion over 5 years: stood at $582.0 in 2017, then tumbled by 195.53% to -$556.0 in 2018, then jumped by 495.68% to $2200.0 in 2019, then slumped by 62.59% to $823.0 in 2020, then sank by 45.08% to $452.0 in 2021.
- Per Business Quant, the three latest RLMD Depreciation and Depletion figures stand at $452.0 (Q2 2021), $806.0 (Q1 2021), and $823.0 (Q4 2020).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 452.00 |
| Jun 30, 2021 | 452.00 |
| Mar 31, 2021 | 806.00 |
| Mar 31, 2021 | 806.00 |
| Dec 31, 2020 | 823.00 |
| Dec 31, 2020 | 823.00 |
| Sep 30, 2020 | 854.00 |
| Sep 30, 2020 | 854.00 |
| Jun 30, 2020 | 1,029.00 |
| Jun 30, 2020 | 1,029.00 |
| Mar 31, 2020 | 1,046.00 |
| Mar 31, 2020 | 1,046.00 |
| Dec 31, 2019 | 2,200.00 |
| Dec 31, 2019 | 2,200.00 |
| Sep 30, 2019 | 1,100.00 |
| Sep 30, 2019 | 1,100.00 |
| Jun 30, 2019 | 2,163.00 |
| Jun 30, 2019 | 2,163.00 |
| Mar 31, 2019 | 1,075.00 |
| Mar 31, 2019 | 1,075.00 |
| Dec 31, 2018 | -556.00 |
| Dec 31, 2018 | -556.00 |
| Sep 30, 2018 | 1,405.00 |
| Sep 30, 2018 | 1,405.00 |
| Mar 31, 2018 | 568.00 |
| Mar 31, 2018 | 568.00 |
| Dec 31, 2017 | 582.00 |
| Dec 31, 2017 | 582.00 |
| Sep 30, 2017 | 548.00 |
| Sep 30, 2017 | 548.00 |
| Jun 30, 2017 | 18,259.00 |
| Jun 30, 2017 | 18,259.00 |
| Mar 31, 2017 | 23,268.00 |
| Mar 31, 2017 | 23,268.00 |
| Dec 31, 2016 | 23,581.00 |
| Dec 31, 2016 | 23,581.00 |
| Sep 30, 2016 | 20,163.00 |
| Sep 30, 2016 | 20,163.00 |
| Jun 30, 2016 | 21,341.00 |
| Jun 30, 2016 | 21,341.00 |
| Mar 31, 2016 | 27,570.00 |
| Mar 31, 2016 | 27,570.00 |
| Dec 31, 2015 | 2,955.00 |
| Dec 31, 2015 | 2,955.00 |
| Sep 30, 2015 | 2,953.00 |
| Sep 30, 2015 | 2,953.00 |
| Jun 30, 2015 | 3,307.00 |
| Jun 30, 2015 | 3,307.00 |
| Mar 31, 2015 | 2,448.00 |
| Mar 31, 2015 | 2,448.00 |
| Dec 31, 2014 | -93.00 |
| Dec 31, 2014 | -93.00 |
| Sep 30, 2014 | 3,594.00 |
| Sep 30, 2014 | 3,594.00 |
| Jun 30, 2014 | 2,330.00 |
| Jun 30, 2014 | 2,330.00 |
| Mar 31, 2014 | 373.00 |
| Mar 31, 2014 | 373.00 |